全球經動脈化療栓塞市場規模、佔有率、成長分析、依產品、最終用戶、技術 - 產業預測 2024-2031

2022年全球經動脈化療栓塞市場規模為168.8億美元，預計將從2023年的178.1億美元成長到2031年的273.3億美元，預測期內（2024-2031年）複合年成長率為5.5%。

在多種因素的推動下，全球經動脈化療栓塞 (TACE) 市場正在經歷顯著的成長和演變。 TACE 是一種主要用於治療肝癌的微創手術，由於全球肝癌發生率不斷上升，其需求激增。飲酒量增加、乙型和丙型肝炎感染流行以及生活方式的改變等因素促使肝癌負擔不斷增加。此外，醫療技術和技術的進步提高了 TACE 手術的有效性和安全性，進一步推動了市場的擴張。此外，越來越多的聯合療法（包括 TACE 與射頻消融或免疫療法等其他療法相結合）的採用正在擴大其應用範圍並推動市場成長。此外，一些國家對 TACE 手術有利的報銷政策，加上正在進行的改善治療結果的研究和開發舉措，預計將維持市場動能。然而，某些地區先進醫療設施的可及性有限以及 TACE 手術相關的高成本等課題可能會在一定程度上阻礙市場成長。總體而言，隨著不斷創新和對個人化醫療的日益關注，全球 TACE 市場預計將在可預見的未來進一步發展。

目錄

執行摘要

• 市場概況
• 命運之輪

研究方法論

• 資訊採購
• 二手和主要資料來源
• 市場規模估計
• 市場假設與限制

母公司市場分析

• 市場概況
• 市場規模
• 市場動態
  • 促進要素
  • 機會
  • 限制
  • 課題

主要市場洞察

• 技術分析
• 定價分析
• 供應鏈分析
• 價值鏈分析
• 市場生態系統
• 智慧財產權分析
• 貿易分析
• 啟動分析
• 原料分析
• 創新矩陣
• 管道產品分析
• 總體經濟指標
• 頂級投資分析
• 成功的關鍵因素
• 競爭程度

市場動態與展望

• 市場動態
  • 促進要素
  • 機會
  • 限制
  • 課題
• 監管環境
• 波特分析
• 對未來顛覆的特別見解

依產品分類的全球經動脈化療栓塞市場

• 市場概況
• 醫院
• 門診手術中心
• 專科診所

依最終用戶分類的全球經動脈化療栓塞市場

• 市場概況
• 草莓
• 蘋果
• 芒果
• 混合水果混合物
• 柑橘
• 異國情調的水果

依技術分類的全球經動脈化療栓塞市場

• 市場概況
• 基於碘化油的 TACE
• 藥物洗脫珠 TACE 技術

全球經動脈化療栓塞市場規模（依地區）

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 拉丁美洲其他地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • MEA 的其餘部分

競爭格局

• 前 5 名企業比較
• 2023 年關鍵參與者的市場定位
• 主要市場參與者所採取的策略
• 最佳制勝策略
• 近期市集活動
• 主要公司市佔率 (%), 2023

主要公司簡介

• Boston Scientific Corporation (US)
• Terumo Corporation (Japan)
• Cook Medical (US)
• Cardinal Health (US)
• Becton, Dickinson and Company (US)
• Guerbet (France)
• AngioDynamics, Inc. (US)
• SIRtex Medical Inc. (Australia)
• Merit Medical Systems Inc. (US)
• Varian Medical Systems, Inc. (US)
• Microvena Therapeutics, Inc. (US)
• RadioMed LLC (US)
• IGT Laboratories (US)
• MicroCath, Inc. (US)
• Spectranetics, Inc. (US)
• Penumbra, Inc. (US)
• Oncotreat SA (Switzerland)
• Vascular Dynamics, Inc. (US)
• Shanghai Jahva Medical Co., Ltd. (China)
• Hangzhou Micro-Tech Co., Ltd. (China)

Global Transarterial Chemoembolization Market size was valued at USD 16.88 billion in 2022 and is poised to grow from USD 17.81 billion in 2023 to USD 27.33 billion by 2031, growing at a CAGR of 5.5% in the forecast period (2024-2031).

The global transarterial chemoembolization (TACE) market is experiencing significant growth and evolution driven by a multitude of factors. TACE, a minimally invasive procedure used primarily in the treatment of liver cancer, has witnessed a surge in demand due to the rising incidence of liver cancer worldwide. Factors such as increasing alcohol consumption, prevalence of hepatitis B and C infections, and changing lifestyles contribute to the growing burden of liver cancer. Additionally, advancements in medical technology and techniques have enhanced the efficacy and safety of TACE procedures, further fueling market expansion. Moreover, the rising adoption of combination therapies, including TACE in conjunction with other treatments such as radiofrequency ablation or immunotherapy, is broadening the scope of its application and driving market growth. Furthermore, favorable reimbursement policies for TACE procedures in several countries, coupled with ongoing research and development initiatives to improve treatment outcomes, are expected to sustain market momentum. However, challenges such as limited accessibility to advanced healthcare facilities in certain regions and the high cost associated with TACE procedures may hinder market growth to some extent. Overall, with continuous innovations and a growing focus on personalized medicine, the global TACE market is poised for further advancement in the foreseeable future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Transarterial Chemoembolization Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Transarterial Chemoembolization Market Segmental Analysis

The global transarterial chemoembolization market is segmented into four major segments i.e. by end-user, product type, technology, and region. Based on end-user, it is divided into hospitals, ambulatory surgical centers, specialty clinics. Based on product type, it is bifurcated as catheters, guidewires, microcatheters, embolic agents, chemotherapeutic agents. Based on technology it is segregated into, lipiodol-based TACE, drug-eluting bead TACE technology. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, Middle East & Africa.

Drivers of the Global Transarterial Chemoembolization Market

The global rise in liver cancer cases and the need for treatments like TACE. Furthermore, as medical procedures continue to advance, the precision and effectiveness of these treatment methods are enhanced, making them more appealing to both patients and doctors. Because minimally invasive techniques assist patients avoid the discomfort associated with traditional treatment approaches, they have also emerged as important drivers of TACE.

Restraints in the Global Transarterial Chemoembolization Market

One of the main market barriers in this instance is the variety of individuals with liver cancer cases and their complexity as a result of differing treatment responses. The degree of intricacy linked with TACE has the potential to limit its applicability and need a customized approach, which might eventually impede its widespread adoption. Strict national restrictions regarding the authorization and payment of medical operations present additional difficulty and limitation. Prolonged regulatory procedures and disparities in reimbursement techniques might make it difficult to integrate TACE into ordinary health care delivery.

Market Trends of the Global Transarterial Chemoembolization Market

The movement in liver cancer treatment toward customized care. Healthcare professionals are investigating tailored TACE depending on patient characteristics and overall health state, including tumor kinds. The general move toward precision medicine to optimize patient outcomes is supported by this trend. The TACE market is also seeing a significant trend in technical improvements. This enhances TACE's performance, which is a continuous research project to increase its accuracy and potency. The most recent advancements in drug-eluting bead and imaging technologies, together with embolic agents, enable to target malignant spots so that therapy can be successful with the least amount of harm to surrounding tissues and organs.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Transarterial Chemoembolization Market by Product

• Market Overview
• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics

Global Transarterial Chemoembolization Market by End-User

• Market Overview
• Strawberry
• apple
• mango
• mixed fruit blends
• citrus
• and exotic fruits

Global Transarterial Chemoembolization Market by Technology

• Market Overview
• Lipiodol-based TACE
• Drug-Eluting Bead TACE Technology

Global Transarterial Chemoembolization Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Boston Scientific Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cook Medical (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guerbet (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AngioDynamics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SIRtex Medical Inc. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merit Medical Systems Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Varian Medical Systems, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Microvena Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RadioMed LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IGT Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MicroCath, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spectranetics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Penumbra, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oncotreat SA (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vascular Dynamics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Jahva Medical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hangzhou Micro-Tech Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments